Abstract: Hypothermia is often used to treat Out of Hospital Cardiac Arrest (OHCA) patients, who often simultaneously receive insulin for stress induced hyperglycemia. This study analyzes insulin sensitivity (S I ) variability profiles of OHCA patients undergoing hypothermic treatment to assess its impact on metabolism particularly during cool period. A retrospective analysis of clinically validated model-based insulin sensitivity is identified using data from 240 patients (9988 hours) treated with hypothermia, shortly after admission at the Intensive Care Unit (ICU). The impact on S I is analyzed per-cohort and perpatient for each period of cool and warm by: 1) median S I [IQR], and 2) Hour-to-hour percentage change in S I , (%Δ S I ) median [IQR]. These non-parametric metrics assess level and hour-to-hour variability of S I , which will be compared over time on 6-hour timescales.
INTRODUCTION
Hyperglycemia is prevalent in critical care (Capes, Hunt et al. 2000 , McCowen, Malhotra et al. 2001 , Mizock 2001 , van den Berghe, Wouters et al. 2001 and increases the risks of further complications and mortality (Capes, Hunt et al. 2000 , van den Berghe, Wouters et al. 2001 , Krinsley 2003 . Glycaemic control has shown benefits in reducing mortality (van den Berghe, Wouters et al. 2001 , Krinsley 2004 , Chase, Shaw et al. 2008 ). However, due in part to excessive metabolic variability (Chase, Le Compte et al. 2011 ) , many studies have found it difficult to reproduce these results (Brunkhorst, Engel et al. 2008 , Investigators, Finfer et al. 2009 , Preiser, Devos et al. 2009 ). Out-of-Hospital Cardiac Arrest (OHCA) patients have low survival rates and often experience hyperglycemia (Taylor, Griffiths et al. 1994 , Neumar, Nolan et al. 2008 . However, these patients belongs to one group who has shown benefit from accurate glycaemic control (AGC), but can be highly insulin resistant and variable, particularly on the first two days of stay (Pretty, Le Compte et al. 2012) .
Hypothermia is often used to treat OHCA patients. In general, it leads to a lowering of metabolic rate that induces changes in energy metabolism. However, its impact on metabolism and insulin resistance in critical illness is unknown, although one of the adverse events associated with hypothermic therapy is a decrease in insulin sensitivity and insulin secretion (Hayashi 2009 ). However, this decrease may not be notable in the cohort that is already highly resistant and variable (Pretty, Le Compte et al. 2012) . Hence, understanding metabolic evolution and variability would enable safer and more accurate glycaemic control using insulin in this cohort.
This study analyses the evolution of a clinically validated model-based insulin sensitivity (S I ) metric (Chase, Suhaimi et al. 2010 , McAuley, Berkeley et al. 2011 in OHCA patients to assess the impact of hypothermia at both a cohort and patient-specific, to enable better understand patient condition and physiology, as well as providing insight to enable safer metabolic management.
METHODS

Patients and Data
A retrospective analysis of glycaemic control data from 240 OHCA patients (9988 hours) treated with hypothermia, shortly after admission in Intensive Care Units (ICUs) of Christchurch Hospital, New Zealand, Erasme Hospital, Belgium and Lausanne Hospital, Switzerland. Patients from Christchurch Hospital (20) were on the SPRINT glycaemic control protocol (Chase, Shaw et al. 2008) , whereas the remaining 220 patients from Erasme (122) and Lausanne (98) Hospitals used local AGC protocols. Blood glucose (BG) and temperature readings were taken 1-2 hourly. Data were divided into three periods: 1) cool (T<=35 o C); 2) idle period of 2 hours as hypothermia was removed; and 3) warm (T>35 o C). A maximum of 24 and a minimum of 15 contiguous hours for each period were considered, ensuring a balance of contiguous data between periods. Demographics are shown in Table 1 . 
Model-based Insulin Sensitivity (S I )
Model-based insulin sensitivity (S I ) in this study is a patientspecific parameter describing the whole body effect of insulin. The analysis of patient-specific insulin sensitivity employs a glucose-insulin system model developed and clinically validated in critical care glycaemic control and insulin sensitivity studies (Chase, Suhaimi et al. 2010 , Evans, Shaw et al. 2011 , Lin, Razak et al. 2011 , McAuley, Berkeley et al. 2011 , Fisk, Le Compte et al. 2012 . It is shown schematically in Figure 1 and is defined: 
Any additional parenteral dextrose is represented by PN(t).
Insulin sensitivity S I is identified hourly from patient data, producing a step-wise hourly varying profile (Hann, Chase et al. 2005) . This profile effectively describes the patients' metabolic behaviour under various time-varying physiologic conditions. The validity and independence of this patientspecific parameter have been validated using data from independent, clinically matched cohorts (Chase, Suhaimi et al. 2010) . 
Analyses and Metrics
S I level and variability during the cool (T<35 o C) and warm (T>35 o C) periods are analysed on per-cohort and per-patient bases using 6-hour blocks defined in Table 2 . S I level and variability are non-Gaussian and thus compared using non-parametric cumulative distribution functions (CDFs) which can be calculated by assigning a probability of 1/n to each datum, orders the data from smallest to largest in value, and calculates the sum of the assigned probabilities to and including each datum. Data is compared using a Wilcoxon rank-sum test for whole-cohort comparisons, and a Wilcoxon signed rank test for patient-specific cool-warm pairs. In all cases, p < 0.05 is considered statistically significant.
RESULTS
S I Level Analysis
Figures 2 and 3 present the cumulative distribution functions (CDFs) of hourly SI level by cohort and median SI perpatient, respectively, using 6-hour blocks. Table 3 presents the increase in median insulin sensitivity and corresponding p-values between successive time blocks. The results suggest that insulin sensitivity levels are initially low during the cool period and significantly increase (p <0.001) over time for the first 36-42 hours (~2 days) of ICU stay. It is evident that the increments between each time block are significantly larger for the first 36 hours of treatment. However, subsequent increases are smaller and not significant.
S I Variability Analysis
Figures 4 and 5 present the CDFs for changes in SI ( ) for each time block per-cohort and per-patient, respectively. Table 5 presents the reductions in SI variability between consecutive blocks. ) percohort for OHCA patients, treated with hypothermia using 6-hour blocks for both cool and warm periods. These results show that SI variability decreases during the first 24 hours (i.e. during cool period). During this period, the difference between the 0-6 hour and 6-12 hour blocks is statistically significant (p <0.001), but comparison between blocks 2-3 and 3-4 are similar. However, the variability rise recorded between the 18-24 hour and 24-30 hour blocks where the transition between cool and warm occurs, shows a sharp significant rise in variability for both cohort and perpatient analyses. The remaining blocks show decreasing variability.
In summary, the increase of S I level is consistent from cool to warm throughout the entire treatment. In contrast, decreased S I variability is inconsistent, particularly during the coolwarm transition period, despite significant variability decreases for the first 24 hours and subsequent 18 hours of treatment.
DISCUSSION
Insulin sensitivity level
The insulin sensitivity level results for both per-cohort and per-patient analyses suggest that OHCA patients undergoing hypothermic treatment have significantly lower insulin sensitivity during the earlier cool period on day 1 than the later warm period on day 2. Both results follow the general trend for insulin sensitivity level for critically ill patients over time and are consistent with other ICU studies (Langouche, Vander Perre et al. 2007 , Pretty, Le Compte et al. 2012 .
Insulin sensitivity variability
Both per-cohort and per-patient analyses suggest that OHCA patients undergoing hypothermic treatment are more variable initially and that S I variability decreases over time. However, this trend is interrupted at cool-warm transition period due to change in body temperature. These results broadly match those of (Pretty et al, 2012) and (Langouche et al, 2007) except for the sudden change at cool-warm transition, and are unique findings for this cohort which will impact glycaemic control.
The Impact of S I variability on glycaemic control
Clinically, these results have shown significant implications for managing glycaemia in view of S I variability. Enhanced S I variability can lead to enhanced variability in BG resulting from a given insulin intervention (Chase, Le Compte et al. 2011) . With low and highly variable insulin sensitivity, glycaemic levels might appear to remain unchanged and difficult to control effectively with exogenous insulin. This situation leads to increased insulin doses during initial treatment. However, coupled with high insulin sensitivity variability (Table 3 ) and increasing sensitivity (Table 2) , it can result in the increased glycaemic variability and increased risk of hypoglycaemia during the first 36 hours of treatment. This issue is especially true during the cool-warm transition where SI rises and variability also rises. Thus, since glycaemic variability and hypoglycaemia are independent risk factors for the critically ill, it is important to understand and manage these patient-specific dynamics, especially those unique to a cohort, when implementing any tight glycaemic control.
Finally, it is important to note that consistently rising S I level is also evident in the biased variability seen in Figure 4 . For the first 36 hours, the plot has zero change below 0.5 on the CDF. Thus, S I is biased towards rising as seen in Figures 2 and 3 . More specifically, these results suggest that AGC protocols should seek to try to regulate insulin usage particularly during the cool period in the first 12-24 hours of ICU stay, while still maintaining glycaemic control to a given target. Due to high levels of insulin resistance and the saturation of insulin action, modulating carbohydrate and nutrition inputs might also be explicitly considered. In particular, early or, excessive nutritional regimes might be avoided or moderated to better manage the metabolic dynamics observed in this study.
CONCLUSION
This study analyses the metabolic evolution of OHCA patients treated with hypothermia. These analyses characterize the metabolic impact of hypothermic treatment on the level and variability of insulin sensitivity to inform control.
Two main conclusions are drawn as a result for these cohorts. i) S I level is much lower during hypothermia and consistently increases over time, both cool and warm periods. ii) Insulin sensitivity is more variable during the cool period and shows contrasting behavior during cool-warm transition period between 18 -30 hours, which indicates that there are major changes in physiology and metabolic conditions between cool and warm as influenced by human body temperature. Otherwise, it decreases over time.
Finally, this study shows the need for patient-specific glycemic management to ensure good control and safety during treatment. These results have significant potential clinical impact on the metabolic treatment of these patients, and changes in clinical therapy are required to safely treat patients as they transition from cool to warm.
